Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918770 | 0.92 | CHRM3 (0.50) | CHRM3NTRK1ATMTDP1SUCNR1 | |
| SCHEMBL4793286 | 0.92 | CHRM3 (0.48) | CHRM3MAPTTHRBNTRK1ATM | |
| SCHEMBL29390454 | 0.91 | CHRM3 (0.46) | CHRM3MAPTNTRK1ATMMEN1 | |
| SCHEMBL303175 | 0.91 | CHRM3 (0.46) | CHRM3MAPTNTRK1ATMMEN1 | |
| SCHEMBL673368 | 0.89 | CHRM3 (0.48) | CHRM3ALDH1A1 | |
| SCHEMBL4920485 | 0.89 | CHRM3 (0.46) | CHRM3MAPTNTRK1ATMTDP1 | |
| SCHEMBL4921835 | 0.89 | SSTR2 (0.44) | CHRM3MAPTNTRK1ATMTDP1 | |
| SCHEMBL16972354 | 0.88 | CHRM3 (0.39) | CHRM3MAPTTHRBNTRK1ATM | |
| SCHEMBL16617799 | 0.88 | CHRM3 (0.44) | CHRM3MAPTNTRK1ATMMEN1 | |
| SCHEMBL29391140 | 0.88 | CHRM3 (0.46) | CHRM3NTRK1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | BASF AKITENGESELLSCHAFT (DE) | 2008-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | CBR3, C1S, PYM1 | CHRM3 222/4885MAPT 4417/4885THRB 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.